CMH Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

CMH Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,049	Closed	-$2.43M	–	45
2023 Q2	$2.43M	Buy	28,049 +964	+4%	+$90.7K	0.65%	43
2023 Q1	$2.63M	Sell	27,085 -14,884	-35%	-$1.54M	0.76%	43
2022 Q4	$4.34M	Sell	41,969 -215	-0.5%	-$20.2K	1.39%	33
2022 Q3	$3.58M	Sell	42,184 -967	-2%	-$86.1K	1.31%	34
2022 Q2	$3.58M	Buy	43,151 +1,664	+4%	+$132K	1.29%	31
2022 Q1	$3.2M	Buy	41,487 +3,911	+10%	+$327K	0.98%	39
2021 Q4	$3.32M	Sell	37,576 -85	-0.2%	-$7.01K	1%	39
2021 Q3	$2.91M	Buy	37,661 +1,735	+5%	+$137K	0.96%	38
2021 Q2	$3M	Buy	35,926 +1,934	+6%	+$153K	1%	37
2021 Q1	$2.57M	Buy	33,992 +879	+3%	+$71.8K	0.97%	38
2020 Q4	$2.9M	Buy	33,113 +7,906	+31%	+$627K	1.06%	35
2020 Q3	$1.92M	Buy	25,207 +3,751	+17%	+$380K	0.82%	39
2020 Q2	$2.65M	Sell	21,456 -1,619	-7%	-$161K	1.26%	32
2020 Q1	$1.95M	Buy	23,075 +1,295	+6%	+$112K	1.14%	42
2019 Q4	$1.84M	Sell	21,780 -21,930	-50%	-$1.66M	0.95%	45
2019 Q3	$2.95M	Buy	43,710 +16,342	+60%	+$1.26M	1.67%	24
2019 Q2	$2.34M	Buy	27,368 +85	+0.3%	+$7.27K	1.38%	33
2019 Q1	$2.42M	Buy	27,283 +14,010	+106%	+$1.3M	1.47%	28
2018 Q4	$1.13M	Buy	13,273 +50	+0.4%	+$4.76K	0.68%	52
2018 Q3	$1.3M	Buy	13,223 +1,585	+14%	+$158K	0.68%	51
2018 Q2	$1.09M	Sell	11,638 -25	-0.2%	-$2.19K	0.63%	50
2018 Q1	$901K	Sell	11,663 -9,775	-46%	-$839K	0.61%	48
2017 Q4	$1.95M	Sell	21,438 -45	-0.2%	-$3.91K	1.29%	29
2017 Q3	$2.01M	Sell	21,483 -165	-0.8%	-$14.6K	1.49%	24
2017 Q2	$1.99M	Sell	21,648 -155	-0.7%	-$14.1K	1.59%	24
2017 Q1	$1.93M	Sell	21,803 -302	-1%	-$26.9K	1.51%	26
2016 Q4	$1.89M	Buy	+22,105	New	+$1.9M	1.65%	21

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CMH Wealth Management's BMRN Position: Q3 2023 in Review

CMH Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 28,049 shares — an estimated $2.43M sold.

CMH Wealth Management first reported a position in BMRN in Q4 2016 and held it in 27 quarters. The position peaked at $4.34M in Q4 2022. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

CMH Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
CMH Wealth Management sold 28,049 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $2.43M.
CMH Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 27 quarters.
CMH Wealth Management's BioMarin Pharmaceuticals position peaked at $4.34M in Q4 2022.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on CMH Wealth Management's 13F filing for Q3 2023, filed 13 Oct 2023.